Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak
In continued collaboration with Rwanda to address the Marburg virus outbreak, the Sabin Vaccine Institute has dispatched approximately 1,000 additional investigational vaccine doses for a randomized clinical trial arm within the ongoing open-label study.
Transformation Through Collaboration: Lasting Impacts of the SEAP Project
Over the past decade, the Surveillance of Enteric Fever in Asia Project (SEAP) has made remarkable strides in understanding typhoid and paratyphoid, diseases that pose a critical public health threat for many regions. This year, SEAP concluded its impactful journey.
See our 2023 Impact Report
For Sabin’s 30th anniversary, we celebrated the milestone year with several high-impact firsts and grew key initiatives, advancing new vaccines for unmet medical needs and turning existing vaccines into vaccinations.
Local Impact, Global Change
Explore how Sabin’s partners drive impact on the ground. Discover their stories here, and check back for updates on new locations and projects.
Confronting Deadly Diseases
Vaccines are our best defense against disease. Yet, we still have lethal diseases that need a vaccine solution urgently. Sabin’s R&D team is tackling two such threats: Sudan ebolavirus and Marburg virus disease. There are no approved vaccines for either of these viruses which have left behind a trail of outbreaks, ending many lives and livelihoods in Africa. Sabin’s vaccines are in Phase 2 clinical trials in Uganda and Kenya.
Making a Case for Vaccines
News & Resources
We make vaccines more accessible, enable innovation and expand immunization across the globe.